Navigation Links
ZIOPHARM Presents Data on Orally Active ZIO-201 at AACR

, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. For more information, visit www.ziopharm.com.

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements for ZIOPHARM Oncology, Inc. that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurance that any of the Company's development efforts relating to its product candidates will be successful, or such product candidates will be successfully commercialized. Other risks that affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of the Company's product candidates, the risk that the results of clinical trials may not support the Company's claims, and risks related to the Company's ability to protect its intellectual property and its reliance on third parties to develop its product candidates. The Company assumes no obligation to update these forward-looking statements, except as required by law.

ZIOP-G

Contact

ZIOPHARM Oncology, Inc.
Investors
Suzanne McKenna, 646-214-0703
smckenna@ziopharm.com
or
Media
Tina Posterli, 917-322-2565
tposterli@r
'"/>




Page: 1 2 3

Related medicine technology :

1. ZIOPHARM to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. ZIOPHARM Presents Data Highlighting Oral ZIO-101 at AACR
3. ZIOPHARM Presents Unique Mechanism Data for Indibulin at AACR
4. ZIOPHARM Presents ZIO-201 Lymphoma Data at ISH
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
7. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
8. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
9. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
10. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
11. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: ZIOPHARM Presents Data Orally Active ZIO AACR
(Date:1/8/2009)...s treated at the initial dose in an ongoing Phase ...d decline after three days , , Conference Call ...ewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc....e first cohort of an ongoing Phase Ib clinical tri...cleoside polymerase inhibitor. ANA598 was very we...
(Date:1/7/2009)...CK, Md., Jan. 7 ImQuest Life Scien...n IND application to the Food and Drug Administrat...ad pyrimidinedione HIV inhibitor IQP-0410. ImQuest...he first quarter of 2009. IQP-0410 is a novel smal...s a nonnucleoside reverse transcriptase inhibitor ...
(Date:1/6/2009)... Expands on Successful Results from prior U.S., U....wswire/ -- Vital Therapies, Inc. (VTI), a developm...nnounced patient enrollment has begun for a random...rial that will study the Extracorporeal Liver Assi...Acute Liver Failure (ALF) under three protocols. T...
(Date:1/6/2009)...LE, Md., Jan. 6 Sequell...y focused on diseases of epidemic potential, annou... the treatment of tuberculosis (TB), was the first...linical program contract to Dynport Vaccine Compan...warded by the National Institute of Allergy and In...
Breaking Medicine Technology:ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 2ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 3ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 4ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 5ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 6ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 3Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3Polyphenon Pharma Receives Orphan Drug Designation for Its Botanical Drug Polyphenon E for the Treatment of CLL 2711 1Polyphenon Pharma Receives Orphan Drug Designation for Its Botanical Drug Polyphenon E for the Treatment of CLL 2711 2Newly discovered monkey is threatened with extinction 4224 1Bone Density Predicts Chances of Breast Cancer 24436 1Bone Density Predicts Chances of Breast Cancer 24436 2Florida Dentist Launches Revolutionary Solution to National Dental Specialist Patient Care Dilemma 24432 1Florida Dentist Launches Revolutionary Solution to National Dental Specialist Patient Care Dilemma 24432 2Florida Dentist Launches Revolutionary Solution to National Dental Specialist Patient Care Dilemma 24432 3
(Date:1/8/2009)..., Board Decision May Be Revealed Friday, January...re/ -- Today, Service Employees International Uni...ce call of the SEIU International Executive Board ...ome and homecare members out of SEIU United Health...te, but delayed the final decision until tomorrow....
(Date:1/8/2009)..., New Allscripts Prenatal Solution Key Factor in ... CHICAGO and ORLANDO, Fla., Jan. 8 /PRNewswire-Fir...an Associates LLC, one of the largest multi-specia..., has selected the Allscripts Enterprise(TM) Elect...their 80 physicians in 18 offices across Central F...
(Date:1/8/2009)..., BETHESDA, Md., Jan. 8 /PRNewswire-FirstCall/ -...pleased to announce that throughout the fourth qua..., Orthotics Center, Rocky Mountain Orthotic-Prosth...Services, Inc., First Coast Orthotics & Prosth.... These acquisitions add patient care centers to e...
(Date:1/8/2009)..., WASHINGTON, Jan. 8 T... D. Olson has been named director, chemical and fo...ices Policy program. Olson, who was formerly deput... Committee on Environment and Public Works, brings...licy and consumer advocacy to Pew. , , "We are...
Breaking Medicine News(10 mins):Health News:SEIU Decision to Force Transfer of Long-Term Care Members Out of United Healthcare Workers Delayed 2Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 2Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 3Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 4Health News:Hanger Orthopedic Group, Inc. Announces Six Acquisitions Totaling $8.9 Million of Annual Net Revenue 2Health News:Veteran Environmental Health Expert Erik D. Olson to Join Pew 2
...of Texas Health Center at Tyler has discovered how...ocess works. Once the process// is thoroughly unde...ulate it, thus preventing excessive bleeding or bl...er, Ph.D., and his team are published in the Aug. ...
...ive up smoking may be more successful than anyone ... to a new study in the July-August 2006// Nursing ... nurses are widely recognized as central to global... of tobacco use," said Dr. Molly C. Dougherty, Nur...
...accepted as a hazard of aging, but researchers act...es are a consequence of aging// or not. Researcher... the Scripps Research Institute have now conducted...is critical for diseases like Alzheimer's. Harmfu...
...mu and Kashmir is having a severe impact on the me...ildren.// More and more women are knocking on th...fe-torn state. Over 50 percent of some 60,000 peop... mental disorders in the past decade have been wom...
Other Medicine News:Health News:Scientist Discovers Crucial Part of Blood-Clotting Process 2Health News:Nurses Can Play Big Role In Helping Patients Quit Smoking 2Health News:Aging Critical For Alzheimer's Disease 2Health News:Aging Critical For Alzheimer's Disease 3Health News:More People Seeking Treatment for Mental Illness in Strife-torn Kashmir 2
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
Medicine Products: